COMy 2019 | CAR-T in myeloma: what is the potential?
CAR T-cell therapy is a growing immunotherapy, but what is its potential for multiple myeloma? Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the recent trial of bb2121 (CRB-402; NCT03274219) and the questions it leaves to be answered, including whether CAR-T is most beneficial during first relapse or as part of consolidation after transplant. Additionally, Prof. McCarthy discusses the options for poor response patients. One thing is clear, it will be an interesting journey. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
Get great new content delivered to your inboxSign up